Amendment ID: S3178-284

Amendment 284

Redomestication of Pharmaceutical Production

Messrs. Tarr and O'Connor move that the proposed new text be amended by inserting after section___  the following section:-

"SECTION_____. There shall be a commission to study and make recommendations relative to the redomestication in the commonwealth of the production of pharmaceutical products, for the purpose of encouraging, supporting, and incenting the production of such products which are currently, or which may be otherwise, produced outside of the United States. The commission shall consist of 19 members, including the Secretary of Economic Affairs, or a designee, whom shall chair the commission, the Secretary of Health and Human Services, two members appointed by the Speaker of the House of Representatives, one member appointed by the Minority Leader of the House of Representatives, two members appointed by the Senate President, one member appointed by the Minority Leader of the Senate, one member appointed by the Attorney General of the commonwealth, whom shall have expertise in the law of intellectual property, and 12 members appointed by the Governor of the commonwealth, two of whom shall represent current manufacturers of pharmaceuticals in the commonwealth, two of whom shall represent businesses engaged in pharmaceutical research and development in the commonwealth, one of whom shall have expertise in manufacturing and materials logistics, two of whom shall represent institutions of higher learning with life sciences and/or business programs in the commonwealth, one of whom shall be an economist with expertise in the life sciences, one of whom shall represent organized labor, two of whom shall represent a patient advocacy organization, and one of whom shall represent consumers.

The commission shall meet not less than quarterly, shall conduct not less than one public hearing, which shall be accessible for remote electronic participation, annually, and shall consult regularly with current and prospective manufacturers of pharmaceutical products in the commonwealth, provided that the commission shall focus on current barriers to pharmaceutical production in Massachusetts and the United States, potential incentives to encourage the return of pharmaceutical production to the commonwealth from facilities outside of the United States and in other states, and the costs and benefits to the commonwealth of such redomestication of production.

The commission shall file a report annually, together with any legislative and regulatory recommendations, with the Executive Office of Economic Affairs, the Executive Office of Health and Human Services, the Joint Committee on Economic Development and Emerging Technologies, the Joint Committee on Health Care Financing, and the clerks of the House and Senate.

The provisions of this section shall expire five years following the passage of this act, unless otherwise terminated, modified, or extended."